Jefferies increased its price target for NVIDIA Corporation to $275 from $250 on January 16, maintaining a Buy rating. The firm told investors the stock "remains pretty cheap," trading at a mid-teens multiple relative to its calendar year 2027 estimate.
Earlier, on January 13, J.P. Morgan reiterated a Buy rating on NVIDIA. The firm pointed to a $1 billion co-innovation partnership with Eli Lilly and a broader shift in pharmaceuticals toward AI "factories." J.P. Morgan stated this supports the view that NVIDIA's GPU infrastructure is becoming pivotal to modern drug discovery and is supporting durable demand.
The firm also cited NVIDIA's expanding strategic role in life sciences and healthcare. It highlighted the company's full-stack approach as a significant operating leverage driver, spanning AI "factories," chips, software frameworks, and domain-specific models. This is primarily because the same core platforms are reusable across several verticals and applications.
J.P. Morgan further stated that NVIDIA's robotics, integrated simulation, and edge-compute stack is allowing the automation of laboratories in healthcare. This could potentially slash costs by orders of magnitude and boost throughput. On the same day, Wells Fargo also reiterated a Buy rating on NVIDIA and set a $265 price target.
NVIDIA Corporation designs and manufactures computer graphics processors, chipsets, and other multimedia software. It operates in the Compute & Networking and Graphics Processing Unit segments.